This is a prospective multicenter clinical study. This study aims to construct an auxiliary decision-making system for lung cancer immunotherapy combined with radiotherapy by fusing three modes of imagomics, clinicopathological features, and molecular pathological features.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
140
Different cohorts received different doses of radiotherapy
Chemotherapy + immunotherapy
Hunan Cancer Hospital
Changsha, Hunan, China
RECRUITINGIntracranial progression-free survival
assessed according to the Response Evaluation Criteria in Solid Tumors RECIST Version 1.1, undergoing enhanced CT/MRI
Time frame: up to 2 years from enrollment
sPFS
assessed according to the Response Evaluation Criteria in Solid Tumors RECIST Version 1.1, undergoing enhanced CT/MRI
Time frame: up to 2 years from enrollment
Objective Response rate
assessed according to the Response Evaluation Criteria in Solid Tumors RECIST Version 1.1, undergoing enhanced CT/MRI
Time frame: up to 2 years from enrollment
overall survival
the time from enrollment until death or the last follow-up
Time frame: up to 2 years from enrollment
number of participants with treatment-related adverse events
number of participants with treatment-related adverse events as assessed by CTCAE v4.0
Time frame: up to 2 years from enrollment
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.